<DOC>
	<DOCNO>NCT00834093</DOCNO>
	<brief_summary>The purpose research study determine effective safe give Epstein-Barr Virus ( EBV ) immunotherapy product participant nasopharyngeal carcinoma ( NPC ) associate EBV come back spread part participant body . The EBV immunotherapy product make white blood cell participant blood take 16 week create . This EBV immunotherapy product may stop cancer cell grow cause tumor disappear .</brief_summary>
	<brief_title>A Phase II Study Epstein-Barr Virus-Specific Immunotherapy Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>Subjects register provide blood sample use create immune therapy product . This take 16 week time receive chemotherapy nasopharynx cancer . When immune product ready chemotherapy stop immunotherapy product give participant infusion . On first day research treatment , participant receive infusion # 1 EBV immunotherapy product . Fourteen day later , participant receive infusion # 2 . Eight week infusion # 2 , research doctor test determine effect EBV immunotherapy product participant tumor . If research doctor think would benefit third infusion EBV immunotherapy product sufficient immunotherapy product remain , participant give infusion # 3 . - Before infusion EBV immunotherapy product participant physical exam , blood work fiberoptic exam nasopharynx need . - Within 28 day receive EBV immunotherapy product first time , evaluate participant tumor use CT scan and/or MRI .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Histologically cytologically proven NPC WHO grade , associate EBV infection document presence EBER expression situ hybridization tumor . Positive EBER stain another institution must confirm pathology review Brigham Women 's Hospital . Other confirmation EBVassociated disease acceptable , EBV DNA situ hybridization , EBER analysis adequate Incurable NPC Recovery toxicity prior NPC therapy grade 1 good 18 year age old Evaluable measurable disease , accord modify RECIST ECOG Performance Status 0 1 Adequate bone marrow , liver renal function outline protocol Radiotherapy primary NPC within 8 week enrollment , radiotherapy reason within 6 week Chemotherapy NPC within 2 week enrollment Other cancer past 5 year , except carcinoma situ cervix bladder , nonmelanomatous skin cancer Uncontrolled central nervous system metastasis Active hepatitis , know HIV , condition require immunosuppressive therapy , include current use high dose systemic corticosteroid Autoimmune disease , systemic lupus erythematosis rheumatoid arthritis , active require current immunosuppressive therapy Active uncontrolled serious infection Women childbearing potential positive pregnancy test breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Epstein-Barr Virus</keyword>
	<keyword>NPC</keyword>
	<keyword>EBV</keyword>
	<keyword>immunotherapy</keyword>
</DOC>